Enjoy complimentary customisation on priority with our Enterprise License!
The beta lactam and beta lactamase inhibitors market share is expected to increase to USD 9.04 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%.
This beta lactam and beta lactamase inhibitors market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers beta lactam and beta lactamase inhibitors market segmentation by route of administration (oral, intravenous, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The beta lactam and beta lactamase inhibitors market report also offers information on several market vendors, including Abbott Laboratories, AbbVie Inc., Aristo Pharmaceuticals Pvt Ltd., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Livealth Biopharma Pvt. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Pragati Biocare Pvt. Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd. among others.
Download the Free Report Sample to Unlock the Beta Lactam and Beta Lactamase Inhibitors Market Size for the Forecast Period and Other Important Statistics
The special regulatory designations is notably driving the beta lactam and beta lactamase inhibitors market growth, although factors such as the intake of wrong medications due to incorrect self-diagnosis may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the beta lactam and beta lactamase inhibitors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Beta Lactam and Beta Lactamase Inhibitors Market Driver
Key Beta Lactam and Beta Lactamase Inhibitors Market Trend
Key Beta Lactam and Beta Lactamase Inhibitors Market Challenge
This beta lactam and beta lactamase inhibitors market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global beta lactam and beta lactamase inhibitors market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the beta lactam and beta lactamase inhibitors market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the beta lactam and beta lactamase inhibitors market encompasses successful business strategies deployed by the key vendors. The beta lactam and beta lactamase inhibitors market is concentrated and the vendors are deploying growth strategies such as mergers and acquisitions to compete in the market.
To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The beta lactam and beta lactamase inhibitors market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the beta lactam and beta lactamase inhibitors market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
37% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for beta lactam and beta lactamase inhibitors in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.
The easy availability of beta lactam and beta lactamase inhibitors over the counter (OTC) will facilitate the beta lactam and beta lactamase inhibitors market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the outbreak of COVID-19 declined the economic growth in the region. To mitigate the risk of the pandemic, lockdowns were imposed by the governments of various countries such as the US, Canada, and Mexico, which restricted business activities in North America. This affected the supply of raw materials for the manufacturing of drugs such as beta-lactam and beta-lactamase inhibitors. However, the lifting of lockdown and resumption of business operations in 2020 resulted in the growth of the regional market. Therefore, the market is expected to grow during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The beta lactam and beta lactamase inhibitors market share growth by the oral segment will be significant during the forecast period. Factors such as increased availability of oral agents with excellent absorption (good bioavailability) that provides adequate blood levels with oral administration and increased pressure on physicians to provide more cost-effective therapies for patients have resulted in increased demand for oral route of administration. This is expected to drive the growth of this segment during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the beta lactam and beta lactamase inhibitors market size and actionable market insights on the post-COVID-19 impact on each segment.
Beta Lactam and Beta Lactamase Inhibitors Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.44% |
Market growth 2022-2026 |
$9.04 billion |
Market structure |
Concentrated |
YoY growth (%) |
4.29 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 37% |
Key consumer countries |
US, Canada, Denmark, China, and India |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Aristo Pharmaceuticals Pvt Ltd., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Johnson and Johnson, Livealth Biopharma Pvt. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Pragati Biocare Pvt. Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Route of Administration
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.